NKTX
Nkarta Inc
NASDAQ: NKTX · HEALTHCARE · BIOTECHNOLOGY
$2.69
-2.89% today
Updated 2026-04-29
Market cap
$201.75M
P/E ratio
—
P/S ratio
1,000,000.00x
EPS (TTM)
$-1.41
Dividend yield
—
52W range
$2 – $4
Volume
0.8M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$14.20
+427.88%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-22.21M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $385.00 |
| Net income | $-119.42M | $-117.50M | $-108.79M | $-104.08M | $-27.41M |
| EPS | — | — | — | — | $-1.41 |
| Free cash flow | $-104.11M | $-114.31M | $-104.11M | $-89.91M | $-22.21M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Nkarta Inc trades at $2.69. Our Smart Value Score of 32/100 indicates the stock is weak. TTM revenue stands at $385.00.
Frequently asked questions
What is Nkarta Inc's stock price?
Nkarta Inc (NKTX) trades at $2.69.
Is Nkarta Inc overvalued?
Smart Value Score 32/100 (Grade F, Strong Sell).
What is the price target of Nkarta Inc (NKTX)?
The analyst target price is $14.20, representing +427.9% upside from the current price of $2.69.
What is Nkarta Inc's revenue?
TTM revenue is $385.00.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1,000,000.00x
ROE-28.90%
Beta0.67
50D MA$2.45
200D MA$2.16
Shares out0.07B
Float0.06B
Short ratio—
Avg volume0.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—